Esophageal Cancer

Detailed Overview

Adenocarcinoma typically arises in the lower third of the esophagus from Barrett's esophagus—a metaplastic response to chronic gastroesophageal reflux disease (GERD). Squamous cell carcinoma occurs predominantly in the upper and middle thirds and is strongly linked to tobacco and alcohol use. Due to the esophagus lacking a serosal layer and possessing an extensive submucosal lymphatic network, tumors spread rapidly to regional lymph nodes and adjacent mediastinal structures. Consequently, most patients present with advanced, incurable disease.

Epidemiology & Demographics

It is the 8th most common cancer and the 6th leading cause of cancer-related deaths worldwide. SCC is most common globally (especially in the Asian 'esophageal cancer belt'), while Adenocarcinoma is now the predominant subtype in Western countries. It occurs mostly in men over the age of 60.

Etiological Mechanism

Adenocarcinoma is driven by chronic acid exposure leading to Barrett's esophagus (intestinal metaplasia), which progresses to dysplasia and carcinoma. SCC is driven by chronic mucosal irritation from carcinogens (tobacco, alcohol) or thermal injury (hot beverages), leading to squamous dysplasia.

Primary Causes

Barrett's Esophagus (Adenocarcinoma)

Tobacco Smoking (Both, but primarily SCC)

Heavy Alcohol Consumption (SCC)

Achalasia (SCC)

• Chronic GERD: Increases the risk of Barrett's esophagus and subsequent Adenocarcinoma by 5-fold.
• Obesity: Increases intra-abdominal pressure (worsening GERD) and is a strong independent risk factor for Adenocarcinoma.
• Alcohol and Tobacco Synergism: Combined use drastically multiplies the risk of developing Squamous Cell Carcinoma.
• Plummer-Vinson Syndrome: Webs, iron deficiency anemia, and glossitis; highly predisposes to upper esophageal SCC.

In Adenocarcinoma, chronic gastric acid and bile salt reflux cause damage to the normal stratified squamous epithelium of the distal esophagus. The tissue adapts by undergoing metaplasia to a columnar phenotype with goblet cells (Barrett's esophagus). Mutations in p53 and over-expression of HER2 and EGFR drive progression to low-grade dysplasia, high-grade dysplasia, and invasive adenocarcinoma. In SCC, chronic noxious stimuli (smoke, alcohol) cause genetic alterations (p53, cyclin D1) in squamous cells, leading to dysplasia. Because the esophagus lacks a serosa, tumors easily invade the trachea, aorta, and pericardium.

Characteristic Clinical Presentation

• Progressive Dysphagia: Difficulty swallowing that starts with solids (like meat/bread) and slowly progresses to liquids as the lumen narrows.
• Unintentional Weight Loss: Rapid loss of >10% body weight due to inability to eat and tumor cachexia.
• Odynophagia: Pain upon swallowing, usually a sign of advanced ulcerating disease.
• Hoarseness: Results from direct tumor invasion of the recurrent laryngeal nerve.

Physical Examination Signs

• Cachexia and muscle wasting
• Supraclavicular lymphadenopathy (Virchow's node)
• Hepatomegaly (if liver metastases are present)

• Tracheoesophageal Fistula: Tumor erosion into the trachea, causing severe aspiration pneumonia.
• Aortic Bleeding: Fatal massive hemorrhage from tumor invasion into the aorta.
• Severe Malnutrition: Requiring jejunostomy tube feeding for survival.

Diagnostic Criteria & Guidelines

Diagnosis is established via Upper Endoscopy (EGD) with direct visualization and multiple forceps biopsies confirming malignant cells (adenocarcinoma or SCC). Clinical staging is then required using EUS and PET/CT to determine resectability.

Differential Diagnosis

• Esophageal Stricture (Benign peptic)
• Achalasia
• Eosinophilic Esophagitis
• Esophageal Leiomyoma

Laboratory Tests & Biomarkers

• Complete Blood Count (CBC): Microcytic anemia from chronic occult bleeding.
• Comprehensive Metabolic Panel: Elevated ALP and transaminases if liver metastases are present.
• HER2/neu expression: Checked on biopsy tissue; positive in ~20% of adenocarcinomas, indicating targeted therapy potential.

Imaging Modalities & Findings

• Endoscopic Ultrasound (EUS):
• FDG PET/CT Scan:
• Barium Swallow:

• Stage I
  Tumor invades lamina propria or submucosa. No lymph node involvement.
• Stage II/III
  Tumor invades muscularis propria or adventitia, with regional lymph node metastasis.
• Stage IV
  Distant metastasis (e.g., liver, lungs, bone, non-regional lymph nodes).

Second-Line & Adjunctive Therapy

For unresectable or Stage IV disease: Palliative systemic chemotherapy (Fluorouracil + Oxaliplatin). Addition of targeted therapy (Trastuzumab) if HER2 positive. Immunotherapy (Nivolumab or Pembrolizumab) combined with chemotherapy is now standard for PD-L1 positive advanced tumors.

Surgical & Procedural Management

Esophagectomy (Ivor Lewis or minimally invasive). Involves removing the affected esophagus and regional lymph nodes, and reconstructing the GI tract by pulling the stomach up into the chest to form a neo-esophagus.

Recommended Lifestyle Changes

• Eat small, frequent, soft, and calorie-dense meals.
• Absolute cessation of smoking and alcohol consumption.
• Sleep with the head of the bed elevated to prevent severe reflux after esophagectomy.

Patient Counseling & Advice

Prepare the patient for the high likelihood of requiring a feeding tube (J-tube) during chemoradiation. Emphasize that surgery carries a long, difficult recovery with permanent changes to eating habits (dumping syndrome, reflux).

Follow-Up & Monitoring Schedule

Surveillance includes clinical visits every 3-6 months for the first 2 years, often with CT chest/abdomen and EGD if symptoms arise, to monitor for local recurrence or metastasis.

Preventive Strategies

Screening EGD for patients with chronic GERD > 5 years plus risk factors (white male, >50, obese) to identify and ablate Barrett's esophagus before cancer develops. Avoidance of tobacco and heavy alcohol use.

Overall poor. The 5-year survival rate is approximately 20%. If diagnosed at an early, localized stage, 5-year survival approaches 45%, but for metastatic disease, it is <5%.